Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30


Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors.

Willis M, Asseburg C, Neslusan C.

Diabetes Res Clin Pract. 2019 Feb;148:222-233. doi: 10.1016/j.diabres.2019.01.005. Epub 2019 Jan 11. Review.


Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge.

Palmer AJ, Si L, Tew M, Hua X, Willis MS, Asseburg C, McEwan P, Leal J, Gray A, Foos V, Lamotte M, Feenstra T, O'Connor PJ, Brandle M, Smolen HJ, Gahn JC, Valentine WJ, Pollock RF, Breeze P, Brennan A, Pollard D, Ye W, Herman WH, Isaman DJ, Kuo S, Laiteerapong N, Tran-Duy A, Clarke PM.

Value Health. 2018 Jun;21(6):724-731. doi: 10.1016/j.jval.2018.02.002. Epub 2018 Apr 9.


Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland.

Soini E, Asseburg C, Taiha M, Puolakka K, Purcaru O, Luosujärvi R.

Adv Ther. 2017 Oct;34(10):2316-2332. doi: 10.1007/s12325-017-0614-8. Epub 2017 Oct 3.


Multivariate Prediction Equations for HbA1c Lowering, Weight Change, and Hypoglycemic Events Associated with Insulin Rescue Medication in Type 2 Diabetes Mellitus: Informing Economic Modeling.

Willis M, Asseburg C, Nilsson A, Johnsson K, Kartman B.

Value Health. 2017 Mar;20(3):357-371. doi: 10.1016/j.jval.2016.10.004. Epub 2016 Dec 1.


Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM).

Willis M, Johansen P, Nilsson A, Asseburg C.

Pharmacoeconomics. 2017 Mar;35(3):375-396. doi: 10.1007/s40273-016-0471-3.


Modelling the Persistence of Disease-Modifying Drug Treatment (DMT) and its Independent Drivers in Finnish Multiple Sclerosis (MS) Patients: Parametric Survival Modelling.

Soini E, Holmberg M, Asseburg C, Sumelahti ML.

Value Health. 2014 Nov;17(7):A400. doi: 10.1016/j.jval.2014.08.911. Epub 2014 Oct 26. No abstract available.


Cost-Utility Analysis (cua) Of First-Line Disease-Modifying Treatments (DMT) Versus Best Supportive Care (Bsc) In Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) Patients.

Soini E, Asseburg C, Sumelahti ML.

Value Health. 2014 Nov;17(7):A399. doi: 10.1016/j.jval.2014.08.906. Epub 2014 Oct 26. No abstract available.


Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data.

Hallinen T, Soini EJ, Asseburg C, Kuosmanen P, Laakkonen A.

BMJ Open. 2014 Feb 27;4(2):e004071. doi: 10.1136/bmjopen-2013-004071.


Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM).

Willis M, Asseburg C, He J.

J Med Econ. 2013 Aug;16(8):1007-21. doi: 10.3111/13696998.2013.809352. Epub 2013 Jun 26.


Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.

Theidel U, Asseburg C, Giannitsis E, Katus H.

Clin Res Cardiol. 2013 Jun;102(6):447-58. doi: 10.1007/s00392-013-0552-7. Epub 2013 Mar 9. Erratum in: Clin Res Cardiol. 2013 Jun;102(6):477.


Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison.

Asseburg C, Peura P, Oksanen T, Turunen J, Purmonen T, Martikainen J.

Int J Technol Assess Health Care. 2012 Oct;28(4):382-9. doi: 10.1017/S0266462312000517. Epub 2012 Sep 26.


Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection.

Asseburg C, Willis M, Löthgren M, Seppälä N, Hakala M, Persson U.

Schizophr Res Treatment. 2012;2012:791468. doi: 10.1155/2012/791468. Epub 2012 May 7.


Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model.

Ramsberg J, Asseburg C, Henriksson M.

PLoS One. 2012;7(8):e42003. doi: 10.1371/journal.pone.0042003. Epub 2012 Aug 2.


The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS).

Manca A, Asseburg C, Bravo Vergel Y, Seymour MT, Meade A, Stephens R, Parmar M, Sculpher MJ.

Value Health. 2012 Jan;15(1):22-31. doi: 10.1016/j.jval.2011.07.008. Epub 2011 Sep 29.


Cost effectiveness of golimumab for the treatment of active psoriatic arthritis.

Cummins E, Asseburg C, Prasad M, Buchanan J, Punekar YS.

Eur J Health Econ. 2012 Dec;13(6):801-9. doi: 10.1007/s10198-011-0335-x. Epub 2011 Jul 1.


[Indirect comparison and network meta-analyses--new tools for the assessment of evidence on the relative efficacy of drugs].

Peura P, Asseburg C, Turunen J, Purmonen T, Martikainen J.

Duodecim. 2011;127(9):900-10. Review. Finnish.


Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.

Asseburg C, Frank M, Köhne CH, Hartmann JT, Griebsch I, Mohr A, Osowski U, Schulten J, Mittendorf T.

Clin Ther. 2011 Apr;33(4):482-97. doi: 10.1016/j.clinthera.2011.04.010.


Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.

Purmonen TT, Pänkäläinen E, Turunen JH, Asseburg C, Martikainen JA.

Acta Oncol. 2011 Apr;50(3):344-52. doi: 10.3109/0284186X.2011.553841. Epub 2011 Feb 8.


Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.

Cummins E, Asseburg C, Punekar YS, Shore E, Morris J, Briggs A, Fenwick E.

Value Health. 2011 Jan;14(1):15-23. doi: 10.1016/j.jval.2010.10.016.


The functional response of a generalist predator.

Smout S, Asseburg C, Matthiopoulos J, Fernández C, Redpath S, Thirgood S, Harwood J.

PLoS One. 2010 May 27;5(5):e10761. doi: 10.1371/journal.pone.0010761.

Supplemental Content

Loading ...
Support Center